SHANGHAI, China, August 21, 2026

Dizal Pharmaceutical announced that emerging clinical data for ZEGFROVY® (sunvozertinib) will be presented at the 2026 World Conference on Lung Cancer (WCLC), taking place September 12–15 in Seoul, South Korea. The presentations will highlight new findings for the EGFR inhibitor in non-small cell lung cancer (NSCLC), including its potential use as an adjuvant treatment after surgery and in combination with anlotinib for previously untreated patients with EGFR mutations and co-mutations.

ZEGFROVY Data to Highlight Earlier NSCLC Treatment

At WCLC 2026, Dizal will present findings from a study evaluating ZEGFROVY as adjuvant treatment in patients with resected stage IB-IIIB NSCLC carrying EGFR exon 20 insertion mutations. According to the company, the emerging efficacy findings support the potential of sunvozertinib as an earlier treatment option for this genetically defined patient population. No new safety signals have been observed in the study, while a randomized pivotal study remains ongoing to further evaluate the approach.The presentation, led by Professor Chang Chen, is titled “Efficacy and Safety of Sunvozertinib as Adjuvant Treatment in Resected Stage IB-IIIB EGFR Exon 20 Insertion Mutated NSCLC.” The data will be presented as Poster P1.159 on September 13, 2026, during the WCLC poster session. The study represents an expansion of clinical development for ZEGFROVY beyond its currently approved setting in previously treated advanced or metastatic NSCLC.

Combination Therapy Shows Antitumor Activity

Dizal will also report updated results from a Phase 2 study of ZEGFROVY combined with anlotinib as first-line treatment for NSCLC patients with EGFR sensitizing mutations and co-mutations. The company describes the regimen as an oral, chemotherapy-free combination that continues to demonstrate robust anti-tumor activity with a manageable safety profile.The updated findings will be presented by Professor Yongchang Zhang under the title “Sunvozertinib Plus Anlotinib as First-line Treatment for NSCLC with EGFR Sensitive Mutations and Co-mutations: Updated Phase II Data.” The presentation, designated Poster P3.207, is scheduled for September 15, 2026. Together, the two WCLC presentations are expected to provide additional insight into the potential role of ZEGFROVY across different stages and molecular subtypes of NSCLC.

Advertisement

cGxPJobs Banner

Approved EGFR Therapy Expands Global Development

ZEGFROVY is an irreversible EGFR inhibitor designed to target a broad spectrum of EGFR mutations while maintaining selectivity for wild-type EGFR. The therapy is currently approved in the United States and China for adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease has progressed during or after platinum-based chemotherapy. Dizal has also submitted supplemental New Drug Applications in China and the United States seeking approval of ZEGFROVY as a first-line treatment for NSCLC with EGFR exon 20 insertion mutations, supported by results from the multinational randomized WU-KONG28 Phase 3 study. Both China’s CDE and the U.S. FDA have granted Breakthrough Therapy Designation for the first-line setting. The company announced in July 2026 that it entered an exclusive license agreement with AstraZeneca granting global development and commercialization rights for ZEGFROVY. The transaction is expected to close during the second half of 2026. Dizal continues to evaluate the medicine in additional NSCLC populations, including patients with EGFR sensitizing, T790M and uncommon mutations, as well as HER2 exon 20 insertion mutations.The upcoming WCLC data add to the clinical development program surrounding ZEGFROVY and EGFR-targeted lung cancer treatment, while ongoing pivotal studies and regulatory reviews will determine the therapy’s potential expansion into earlier lines of NSCLC care.

Source: Dizal Pharmaceutical press relese